CDTX – cidara therapeutics, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Days Volatility
Open
Prior Close

YTD

1 Day

CDTX

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

1/7

07:01 am

cdtx

Merck to Complete Acquisition of Cidara Therapeutics [Yahoo! Finance]

Neutral Report

Merck to Complete Acquisition of Cidara Therapeutics [Yahoo! Finance]

Report

1/2

03:41 am

cdtx

Cidara Therapeutics (CDTX) Rockets 722% in 2025 on Merck $9.2-Billion Merger [Yahoo! Finance]

Low Report

Cidara Therapeutics (CDTX) Rockets 722% in 2025 on Merck $9.2-Billion Merger [Yahoo! Finance]

Report

1/2

02:13 am

cdtx

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? [Yahoo! Finance]

Low Report

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? [Yahoo! Finance]

Report

12/17

12:06 pm

cdtx

Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights

Low Report

Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights

Report

12/8

02:40 pm

cdtx

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--SMLR, MRSN, CDTX, and RYI

Low Report

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--SMLR, MRSN, CDTX, and RYI

Report

11/28

12:37 pm

cdtx

Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their Rights

Low Report

Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their Rights

Report

11/24

08:00 am

cdtx

Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations

Low Report

Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations

Report

11/21

05:30 pm

cdtx

SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-NUVSF, NDTAF, THS, and CDTX

Low Report

SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-NUVSF, NDTAF, THS, and CDTX

Report

Date

Time

Symbol

Company Name

Action

%Chg

11/6/2025

04:07 pm

cdtx

cidara therapeutics, inc.

MISS Report

3.8%

cidara therapeutics, inc.

Report

8/7/2025

04:05 pm

cdtx

cidara therapeutics, inc.

BEAT Report

0.4%

cidara therapeutics, inc.

Report

5/8/2025

04:15 pm

cdtx

cidara therapeutics, inc.

BEAT Report

-2.7%

cidara therapeutics, inc.

Report

Date

Time

Action

From

Firm

Impact

%Chg

11/18

09:14 am

Reiterates

Buy

Neutral

Guggenheim

Low

Report

0.3%

Report

11/18

09:14 am

Reiterates

Buy

Neutral

Guggenheim

Low

Report

0.3%

Report

11/18

09:05 am

Downgrades

Buy

Neutral

Guggenheim

Low

Report

0.3%

Report

11/18

09:05 am

Downgrades

Buy

Neutral

Guggenheim

Low

Report

0.3%

Report

11/17

01:23 pm

Downgrades

BUY

NEUTRAL

GUGGENHEIM

Low

Report

-0.1%

Report

11/17

01:23 pm

Downgrades

BUY

NEUTRAL

GUGGENHEIM

Low

Report

-0.1%

Report

11/17

10:23 am

Downgrades

Overweight

Equal Weight

Morgan Stanley

Low

Report

0.1%

Report

11/17

10:23 am

Downgrades

Outperform

Sector Perform

Royal Bank Of Canada

Low

Report

0.1%

Report

Date

Time

Symbol

Headline

Impact

1/7

08:21 pm

cdtx

Form 4 Cidara Therapeutics, For: Jan 07 Filed by: Resnick Joshua

Neutral Report

Form 4 Cidara Therapeutics, For: Jan 07 Filed by: Resnick Joshua

Report

1/7

08:20 pm

cdtx

Form 4 Cidara Therapeutics, For: Jan 07 Filed by: Merson James

Neutral Report

Form 4 Cidara Therapeutics, For: Jan 07 Filed by: Merson James

Report

1/7

08:20 pm

cdtx

Form 4 Cidara Therapeutics, For: Jan 07 Filed by: Spencer Ryan

Neutral Report

Form 4 Cidara Therapeutics, For: Jan 07 Filed by: Spencer Ryan

Report

1/7

08:20 pm

cdtx

Form 4 Cidara Therapeutics, For: Jan 07 Filed by: Canale-Theakston Carin

Neutral Report

Form 4 Cidara Therapeutics, For: Jan 07 Filed by: Canale-Theakston Carin

Report

1/7

08:19 pm

cdtx

Form 4 Cidara Therapeutics, For: Jan 07 Filed by: Bassler Bonnie L

Neutral Report

Form 4 Cidara Therapeutics, For: Jan 07 Filed by: Bassler Bonnie L

Report

1/7

08:18 pm

cdtx

Form 4 Cidara Therapeutics, For: Jan 07 Filed by: Mineo Chrysa

Neutral Report

Form 4 Cidara Therapeutics, For: Jan 07 Filed by: Mineo Chrysa

Report

1/7

08:18 pm

cdtx

Form 4 Cidara Therapeutics, For: Jan 07 Filed by: Schroeder Theodore R

Neutral Report

Form 4 Cidara Therapeutics, For: Jan 07 Filed by: Schroeder Theodore R

Report

1/7

08:17 pm

cdtx

Form 4 Cidara Therapeutics, For: Jan 07 Filed by: Stein Jeffrey

Neutral Report

Form 4 Cidara Therapeutics, For: Jan 07 Filed by: Stein Jeffrey

Report

Stock Stats

News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings

Order Stats
Sub-Penny

Odd lot

Avg. bid-ask spread

Avg. bid-ask size

Shares at ask/bid

Off exchange

Main News & Impact Reports

Don’t Miss Out On The Next BIG Stock Move

Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.